First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Table 1 Characteristics of Included Studies

Study	Type	Time	Background therapy, lines of treatment	Outcomes	Followup (media, months)	Jadad/NOS
Venook AP 2017 [6]	RCT	Nov 2005-Mar 2012	mFOLFOX6 or FOLFIRI	OS, PFS and ORR, complete or partial response, 60-day mortality, arterial thrombotic events	47.4	Jadad 5
FIRE-3 [5, 24]	RCT	Mar 2007-Sep 2012	FOLFIRI	objective response, OS, PFS, depth of response, secondary resection of liver metastases with curative intent, early ORR, time to response	40.3	Jadad 5
Houts AC 2017 [26]	OCS	Apr 2005 and Mar 2012	FOLFIRI or FOLFOX	OS, PFS	–	NOS 8
Bai L 2016 [27]	OCS	Jan 2009 - Dec 2013	mFOLFOX-6, XELOX, or FOLFIRI	OS, PFS, ORR, DCR	–	NOS 8
Yang YH 2014 [28]	OCS	Apr 2005-Mar 2012	FOLFIRI or FOLFOX	OS, PFS, ORR, DCR	–	NOS 8

RCT Randomized Clinical Trial, OCS observational cohort study, PFR progression-free rate, PFS Progression free survival, ORR objective response rate, OS overall survival, DCR isease control rate

ISSN: 1471-2407